Toward the prevention of coronavirus infection: what role can polymers play?
Source abstract
Abstract
Severe acute respiratory syndrome-associated coronavirus 2 has caused a global public health crisis with high rates of infection and mortality. Treatment and prevention approaches include vaccine development, the design of small-molecule antiviral drugs, and macromolecular neutralizing antibodies. Polymers have been designed for effective virus inhibition and as antiviral drug delivery carriers. This review summarizes recent progress and provides a perspective on polymer-based approaches for the treatment and prevention of coronavirus infection. These polymer-based partners include polyanion/polycations, dendritic polymers, macromolecular prodrugs, and polymeric drug delivery systems that have the potential to significantly improve the efficacy of antiviral therapeutics.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · SARS-CoV-2 detection and testing · Antimicrobial agents and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Structural and functional basis of SARS-CoV-2 entry by using human ACE210.1016/j.cell.2020.03.045 ↗
2. Broad-spectrum coronavirus antiviral drug discovery10.1080/17460441.2019.1581171 ↗
3. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE210.1371/journal.ppat.1007236 ↗
4. SARS and MERS: recent insights into emerging coronaviruses10.1038/nrmicro.2016.81 ↗
5. Coronavirus disease 2019: coronaviruses and blood safety10.1016/j.tmrv.2020.02.003 ↗
6. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review10.7326/M20-3213 ↗
7. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS)10.1016/S0140-6736(03)13168-6 ↗
8. Lab-on-mask for remote respiratory monitoring10.1021/acsmaterialslett.0c00299 ↗
9. Sensors and analytical technologies for air quality: particulate matters and bioaerosols10.1002/asia.202001051 ↗
10. Face masks in the new COVID-19 normal: materials, testing, and perspectives
11. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate covid-19: a randomized clinical trial10.1001/jama.2020.16349 ↗
12. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy10.1016/j.drup.2020.100719 ↗
13. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques10.1038/s41586-020-2607-z ↗
14. Safety and immunogenicity of two rna-based covid-19 vaccine candidates10.1056/NEJMoa2027906 ↗
15. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses10.1016/j.it.2020.03.007 ↗
16. Inhibition of SARS-associated coronavirus infection and replication by RNA interference10.1001/jama.290.20.2665 ↗
17. Valorization of disposable COVID-19 mask through the thermo-chemical process10.1016/j.cej.2020.126658 ↗
18. The efficacy of plant-based ionizers in removing aerosol for COVID-19 mitigation10.34133/2021/2173642 ↗
19. Multifunctional antimicrobial nanofiber dressings containing ε-polylysine for the eradication of bacterial bioburden and promotion of wound healing in critically colonized wounds10.1021/acsami.9b21683 ↗
20. Mussel-inspired durable antimicrobial contact lenses: the role of covalent and noncovalent attachment of antimicrobials10.1021/acsbiomaterials.0c00229 ↗
21. Protective action of linear polyethylenimine against Staphylococcus aureus colonization and exaggerated inflammation in vitro and in vivo10.1021/acsinfecdis.9b00102 ↗
22. Wound healing properties of magnesium mineralized antimicrobial nanofibre dressings containing chondroitin sulphate–a comparison between blend and core–shell nanofibres10.1039/D0BM00530D ↗
23. Cationic poly ([R]-3-hydroxybutyrate) copolymers as antimicrobial agents10.1002/mabi.201800466 ↗
24. Sanitizing agents for virus inactivation and disinfection10.1002/viw2.16 ↗
25. Toward nanotechnology-enabled approaches against the COVID-19 pandemic10.1021/acsnano.0c03697 ↗
26. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis10.1016/S0140-6736(20)31142-9 ↗
27. Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study
28. Household materials selection for homemade cloth face coverings and their filtration efficiency enhancement with triboelectric charging10.1021/acs.nanolett.0c02211 ↗
29. Study of new protective clothing against SARS using semi-permeable PTFE/PU membrane10.1016/j.eurpolymj.2003.11.014 ↗
30. Polymeric drugs: advances in the development of pharmacologically active polymers10.1016/j.jconrel.2015.09.043 ↗
31. Comparing the binding interactions in the receptor binding domains of SARS-CoV-2 and SARS-CoV10.1021/acs.jpclett.0c01064 ↗
32. Influence of sulfur amino acids on copper toxicity in chicks10.1093/jn/109.1.91 ↗
33. Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo10.1128/jvi.2.9.886-893.1968 ↗
34. Macromolecular antiviral agents against Zika, Ebola, SARS, and other pathogenic viruses10.1002/adhm.201700748 ↗
35. Novel quaternary phosphonium-type cationic polyacrylamide and elucidation of dual-functional antibacterial/antiviral activity10.1039/C4RA08634A ↗
36. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens10.1038/nbt.2344 ↗
37. Decreasing herpes simplex viral infectivity in solution by surface-immobilized and suspended N,N-dodecyl,methyl-polyethylenimine10.1007/s11095-012-0825-2 ↗
38. Topical application of polyethylenimine as a candidate for novel prophylactic therapeutics against genital herpes caused by herpes simplex virus10.1007/s00705-013-1829-x ↗
39. Polymeric coatings that inactivate both influenza virus and pathogenic bacteria10.1073/pnas.0608803103 ↗
40. Agmatine-containing poly(amidoamine)s as a novel class of antiviral macromolecules: structural properties and in vitro evaluation of infectivity inhibition10.1128/AAC.03420-14 ↗
41. The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice10.1016/j.biomaterials.2016.01.055 ↗
42. Cooperative orthogonal macromolecular assemblies with broad spectrum antiviral activity, high selectivity, and resistance mitigation10.1021/acs.macromol.6b00091 ↗
43. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients10.7150/thno.46691 ↗
44. A pilot study of the antiviral activity of anionic and cationic polyamidoamine dendrimers against the Middle East respiratory syndrome coronavirus10.1002/jmv.25928 ↗
45. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE210.1016/j.cell.2020.09.033 ↗
46. Multivalent flexible nanogels exhibit broad-spectrum antiviral activity by blocking virus entry10.1021/acsnano.8b01616 ↗
47. Polysaccharides as antiviral agents - antiviral activity of carrageenan10.1128/AAC.31.9.1388 ↗
48. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo10.1038/s41467-018-06349-0 ↗
49. Cholesterol dependence of newcastle disease virus entry10.1016/j.bbamem.2011.12.004 ↗
50. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release10.1128/JVI.79.15.9862-9871.2005 ↗
51. The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus Beaudette strain10.1371/journal.pone.0170123 ↗
52. Modified cyclodextrins as broad-spectrum antivirals10.1126/sciadv.aax9318 ↗
53. HTCC: broad range inhibitor of coronavirus entry10.1371/journal.pone.0156552 ↗
54. Novel polymeric inhibitors of HCoV-NL6310.1016/j.antiviral.2012.11.006 ↗
55. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation10.1016/j.jconrel.2014.09.032 ↗
56. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs10.1021/bm401048s ↗
57. Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV10.1039/C4SC02754J ↗
58. Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug10.1039/c3cc00315a ↗
59. Polyanionic macromolecular prodrugs of ribavirin: antiviral agents with a broad spectrum of activity10.1002/adhm.201500841 ↗
60. Macromolecular prodrugs of ribavirin: polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects10.1016/j.jconrel.2018.02.012 ↗
61. Polymer-based nanomaterials and applications for vaccines and drugs10.3390/polym10010031 ↗
62. A new highly transparent injectable PHA-based thermogelling vitreous substitute10.1039/C9BM01603A ↗
63. Recent progress in polyhydroxyalkanoates-based copolymers for biomedical applications10.1002/biot.201900283 ↗
64. Zinc diethyldithiocarbamate as a catalyst for synthesising biomedically-relevant thermogelling polyurethanes10.1039/D0MA00734J ↗
65. Recent advances in supramolecular hydrogels for biomedical applications10.1016/j.mtadv.2019.100021 ↗
66. Supramolecular thermogels from branched PCL-containing polyurethanes10.1039/D0RA07426H ↗
67. Induction of robust immune responses by CpG-ODN-loaded hollow polymeric nanoparticles for antiviral and vaccine applications in chickens10.2147/IJN.S241492 ↗
68. Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against Middle East respiratory syndrome coronavirus10.1002/adfm.201807616 ↗
69. Poly (d,l-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic diarrhea virus infection in piglets10.1016/j.vaccine.2017.10.054 ↗
70. Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs
71. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in PLGA nanoparticles10.1371/journal.pone.0082648 ↗
72. PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs10.1016/j.vetmic.2013.04.029 ↗
73. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus10.1038/s41598-017-13316-0 ↗
74. O-2'-hydroxypropyltrimethyl ammonium chloride chitosan nanoparticles for the delivery of live Newcastle disease vaccine10.1016/j.carbpol.2015.05.008 ↗
75. Quaternized chitosan nanoparticles loaded with the combined attenuated live vaccine against Newcastle disease and infectious bronchitis elicit immune response in chicken after intranasal administration10.1080/10717544.2017.1388450 ↗
76. Enhancing mucosal immune response of newcastle disease virus DNA vaccine using N-2-hydroxypropyl trimethylammonium chloride chitosan and N,O-carboxymethyl chitosan nanoparticles as delivery carrier10.1021/acs.molpharmaceut.7b00826 ↗
77. Chitosan, hydroxypropyltrimethyl ammonium chloride chitosan and sulfated chitosan nanoparticles as adjuvants for inactivated Newcastle disease vaccine10.1016/j.carbpol.2019.115423 ↗
78. Adjuvant effects of chitosan and calcium phosphate particles in an inactivated Newcastle disease vaccine10.1637/10510-020413-Reg.1 ↗
79. Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles10.1371/journal.pone.0053314 ↗
80. Preparation and efficacy of Newcastle disease virus DNA vaccine encapsulated in chitosan nanoparticles10.2147/IJN.S54226 ↗
81. [Study on immune efficacy of Newcastle disease chitosan microsphere vaccine]
82. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine10.2147/IJN.S70633 ↗
83. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses10.1186/1471-2172-11-65 ↗
84. DNA vaccine encoding spike protein of SARS-coronavirus loaded polyethylenimine elicits antigen-specific immune responses in mice immunized through intranasal route (42.8)
85. Induction of dendritic cell maturation and activation by a potential adjuvant, 2-Hydroxypropyl-beta-cyclodextrin10.3389/fimmu.2016.00435 ↗
86. Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates10.1007/s13346-020-00725-4 ↗
87. The lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-210.1016/j.ijpharm.2020.119689 ↗
88. Improved antiviral activity in vitro of ribavirin against measles virus after complexation with cyclodextrins10.1016/j.antiviral.2004.01.003 ↗
89. Characterization of cyclodextrin complexes of camostat mesylate by ESI mass spectrometry and NMR spectroscopy10.1016/j.molstruc.2009.09.025 ↗
90. Enhanced stability of oral insulin in targeted peptide ligand trimethyl chitosan nanoparticles against trypsin10.3109/02652048.2015.1065920 ↗
91. Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: in silico prediction; effects of derivatization, molar ratio and preparation method10.1016/j.carbpol.2019.115287 ↗
92. Strategies, design, and chemistry in siRNA delivery systems10.1016/j.addr.2019.05.004 ↗
93. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells10.1021/ja044941d ↗
94. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer10.1016/j.jconrel.2008.03.008 ↗
95. Self-assembled siRNA-PLGA conjugate micelles for gene silencing10.1016/j.jconrel.2010.12.007 ↗
96. Alkane-modified short polyethyleneimine for siRNA delivery10.1016/j.jconrel.2011.11.030 ↗
97. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight10.1038/nnano.2014.84 ↗
98. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic10.1021/mp900015y ↗
99. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles10.1038/nature08956 ↗
100. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system10.1016/j.ymthe.2006.04.010 ↗